CEP-33779 antagonizes ATP-binding cassette subfamily B member 1 mediated multidrug resistance by inhibiting its transport function

Biochemical Pharmacology

Volumn 91, Issue 2, 2014, Pages 144-156

  Tang, Shang Jun ^a,b   Chen, Li Kun ^b   Wang, Fang ^b   Zhang, Yun Kai ^d   Huang, Zhen Cong ^b   To, Kenneth Kin Wah ^c   Wang, Xiao Kun ^b   Talele, Tanaji T ^d   Chen, Zhe Sheng ^d   Chen, Wei Qiang ^a   Fu, Li Wu ^b  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d ST JOHN'S UNIVERSITY   (United States)

Author keywords

ABCB1 P glycoprotein; CEP 33779; Chemotherapeutic agents; JAK2 inhibitor; Multidrug resistance (MDR)

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CEP 33779; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; JANUS KINASE 2; MESSENGER RNA; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; SHORT HAIRPIN RNA; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE; JANUS KINASE 2 INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DOWN REGULATION; DRUG ANTAGONISM; DRUG BINDING; DRUG CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; HYDROPHOBICITY; MOLECULAR DOCKING; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; XENOGRAFT; DRUG ACCUMULATION; PROTEIN TRANSPORT; SQUAMOUS CELL CARCINOMA CELL LINE; TUMOR GROWTH;

ABCB1/P-GLYCOPROTEIN; CEP-33779; CEP-33779 (PUBCHEM CID: 57336812); CHEMOTHERAPEUTIC AGENTS; DOXORUBICIN (PUBCHEM CID: 31703) RHODAMINE 123 (PUBCHEM CID: 65217); JAK2 INHIBITOR; MULTIDRUG RESISTANCE (MDR); VERAPAMIL (PUBCHEM CID: 62969); VINCRISTINE (PUBCHEM CID: 5978);

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HETEROGRAFTS; HUMANS; MICE; MICE, NUDE; MOLECULAR STRUCTURE; NEOPLASMS, EXPERIMENTAL; P-GLYCOPROTEIN; PYRIDINES; REAL-TIME POLYMERASE CHAIN REACTION; RHODAMINE 123; TOPOTECAN; TRIAZOLES;

EID: 84906790673     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.07.008     Document Type: Article

References (50)

1. J.I. Fletcher, M. Haber, M.J. Henderson, and M.D. Norris ABC transporters in cancer: more than just drug efflux pumps Nat Rev Cancer 10 2010 147 156
2. R. Perez-Tomas Multidrug resistance: retrospect and prospects in anti-cancer drug treatment Curr Med Chem 13 2006 1859 1876
3. H. Glavinas, P. Krajcsi, J. Cserepes, and B. Sarkadi The role of ABC transporters in drug resistance, metabolism and toxicity Curr Drug Deliv 1 2004 27 42
4. V. Vasiliou, K. Vasiliou, and D.W. Nebert Human ATP-binding cassette (ABC) transporter family Hum Genomics 3 2009 281 290
5. A.K. Tiwari, K. Sodani, C.L. Dai, C.R. Ashby Jr., and Z.S. Chen Revisiting the ABCs of multidrug resistance in cancer chemotherapy Curr Pharm Biotechnol 12 2011 570 594
6. B. Sarkadi, L. Homolya, G. Szakacs, and A. Varadi Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system Physiol RevV 86 2006 1179 1236 (Pubitemid 44521651)
7. S.V. Ambudkar, S. Dey, C.A. Hrycyna, M. Ramachandra, I. Pastan, and M.M. Gottesman Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu Rev Pharmacol Toxicol 39 1999 361 398 (Pubitemid 29222564)
8. G.D. Leonard, T. Fojo, and S.E. Bates The role of ABC transporters in clinical practice The Oncologist 8 2003 411 424 (Pubitemid 37238869)
9. G. Szakacs, J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, and M.M. Gottesman Targeting multidrug resistance in cancer Nat Rev Drug Discov 5 2006 219 234 (Pubitemid 43336035)
10. M. He, and M.J. Wei Reversing multidrug resistance by tyrosine kinase inhibitors Chin J Cancer 31 2012 126 133
11. G.D. Kruh, and M.G. Belinsky The MRP family of drug efflux pumps Oncogene 22 2003 7537 7552 (Pubitemid 37487175)
12. L. Doyle, and D.D. Ross Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) Oncogene 22 2003 7340 7358 (Pubitemid 37487163)
13. K. Sodani, A. Patel, N. Anreddy, S. Singh, D.H. Yang, and R.J. Kathawala et al. Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo Biochem Pharmacol 89 2014 52 61
14. T. Kitazaki, M. Oka, Y. Nakamura, J. Tsurutani, S. Doi, and M. Yasunaga et al. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells Lung Cancer 49 2005 337 343 (Pubitemid 41139146)
15. C.L. Dai, A.K. Tiwari, C.P. Wu, X.D. Su, S.R. Wang, and D.G. Liu et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2 Cancer Res 68 2008 7905 7914
16. Y.J. Mi, Y.J. Liang, H.B. Huang, H.Y. Zhao, C.P. Wu, and F. Wang et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters Cancer Res 70 2010 7981 7991
17. C.L. Dai, Y.J. Liang, Y.S. Wang, A.K. Tiwari, Y.Y. Yan, and F. Wang et al. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2 Cancer Lett 279 2009 74 83
18. M.M. Seavey, L.D. Lu, K.L. Stump, N.H. Wallace, W. Hockeimer, and T.M. O'Kane et al. Therapeutic efficacy of CEP-33779, a novel selective JAK2 inhibitor, in a mouse model of colitis-induced colorectal cancer Mol Cancer Ther 11 2012 984 993
19. J.Y. Zhang, H.Y. Wu, X.K. Xia, Y.J. Liang, Y.Y. Yan, and Z.G. She et al. Anthracenedione derivative 1403P-3 induces apoptosis in KB and KBv200 cells via reactive oxygen species-independent mitochondrial pathway and death receptor pathway Cancer Biol Ther 6 2007 1413 1421
20. L. Fu, Y. Liang, L. Deng, Y. Ding, L. Chen, and Y. Ye et al. Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance Cancer Chemother Pharmacol 53 2004 349 356 (Pubitemid 38392360)
21. R.W. Robey, Y. Honjo, K. Morisaki, T.A. Nadjem, S. Runge, and M. Risbood et al. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity Brit J Cancer 89 2003 1971 1978 (Pubitemid 37533279)
22. R. Tang, A.M. Faussat, P. Majdak, J.Y. Perrot, D. Chaoui, and O. Legrand et al. Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1 Leukemia 18 2004 1246 1251 (Pubitemid 39023135)
23. R.W. Robey, S. Shukla, E.M. Finley, R.K. Oldham, D. Barnett, and S.V. Ambudkar et al. Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)) Biochem Pharmacol 75 2008 1302 1312
24. L.M. Chen, X.P. Wu, J.W. Ruan, Y.J. Liang, Y. Ding, and Z. Shi et al. Screening novel, potent multidrug-resistant modulators from imidazole derivatives Oncol Res 14 2004 355 362 (Pubitemid 39070676)
25. Z. Shi, Y.J. Liang, Z.S. Chen, X.W. Wang, X.H. Wang, and Y. Ding et al. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo Cancer Biol Ther 5 2006 39 47 (Pubitemid 43234976)
26. W.J. Zhou, X. Zhang, C. Cheng, F. Wang, X.K. Wang, and Y.J. Liang et al. Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein Brit. J Pharmacol 166 2012 1669 1683
27. L.M. Chen, Y.J. Liang, J.W. Ruan, Y. Ding, X.W. Wang, and Z. Shi et al. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318 J Pharm Pharmacol 56 2004 1061 1066 (Pubitemid 39140063)
28. A. Venne, S. Li, R. Mandeville, A. Kabanov, and V. Alakhov Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells Cancer Res 56 1996 3626 3629 (Pubitemid 26272000)
29. T. Sumizawa, Z.S. Chen, Y. Chuman, K. Seto, T. Furukawa, and M. Haraguchi et al. Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P Mol Pharmacol 51 1997 399 405 (Pubitemid 27118475)
30. K. Sodani, A.K. Tiwari, S. Singh, A. Patel, Z.J. Xiao, and J.J. Chen et al. GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance Biochem Pharmacol 83 2012 1613 1622
31. X.Q. Zhao, J.D. Xie, X.G. Chen, H.M. Sim, X. Zhang, and Y.J. Liang et al. Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo Mol Pharmacol 82 2012 47 58
32. K.J. Livak, and T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method Methods 25 2001 402 408 (Pubitemid 34164012)
33. S.V. Ambudkar Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells Methods Enzymol 292 1998 504 514 (Pubitemid 29343911)
34. Z. Shi, X.X. Peng, I.W. Kim, S. Shukla, Q.S. Si, and R.W. Robey et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance Cancer Res 67 2007 11012 11020 (Pubitemid 350145931)
35. J. Li, K.F. Jaimes, and S.G. Aller Refined structures of mouse P-glycoprotein Protein Sci 23 2014 34 46
36. M. Hedvat, D. Huszar, A. Herrmann, J.M. Gozgit, A. Schroeder, and A. Sheehy et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors Cancer Cell 16 2009 487 497
37. X. Xu, R.F. Liu, X. Zhang, L.Y. Huang, F. Chen, and Q.L. Fei et al. DLK1 as a potential target against cancer stem/progenitor cells of hepatocellular carcinoma Mol Cancer Ther 11 2012 629 638
38. N. Benabbou, P. Mirshahi, M. Cadillon, J. Soria, A. Therwath, and M. Mirshahi Hospicells promote upregulation of the ATP-binding cassette genes by insulin-like growth factor-I via the JAK2/STAT3 signaling pathway in an ovarian cancer cell line Int J Oncol 43 2013 685 694
39. A. Pardanani JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials Leukemia 22 2008 23 30
40. L.L. Marotta, V. Almendro, A. Marusyk, M. Shipitsin, J. Schemme, and S.R. Walker et al. The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors J Clin Invest 121 2011 2723 2735
41. B.J. Dugan, D.E. Gingrich, E.F. Mesaros, K.L. Milkiewicz, M.A. Curry, and A.L. Zulli et al. A selective, orally bioavailable 1,2,4-triazolo[1,5-a] pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779 J Med Chem 55 2012 5243 5254
42. C. Cheng, Z.G. Liu, H. Zhang, J.D. Xie, X.G. Chen, and X.Q. Zhao et al. Enhancing chemosensitivity in ABCB1- and ABCG2-overexpressing cells and cancer stem-like cells by an Aurora kinase inhibitor CCT129202 Mol Pharmaceut 9 2012 1971 1982
43. Q.F. Xiang, F. Wang, X.D. Su, Y.J. Liang, L.S. Zheng, and Y.J. Mi et al. Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance Cell Oncol 34 2011 33 44
44. K.J. Liu, J.H. He, X.D. Su, H.M. Sim, J.D. Xie, and X.G. Chen et al. Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo Int J Cancer 132 2013 224 235
45. K. Al Zaid Siddiquee, and J. Turkson STAT3 as a target for inducing apoptosis in solid and hematological tumors Cell Res 18 2008 254 267 (Pubitemid 351206162)
46. Z. Duan, R. Foster, D.A. Bell, J. Mahoney, K. Wolak, and A. Vaidya et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer Clin Cancer Res 12 2006 5055 5063 (Pubitemid 44453331)
47. F. Klepsch, I. Jabeen, P. Chiba, and G.F. Ecker Pharmacoinformatic approaches to design natural product type ligands of ABC-transporters Curr Pharm Des 16 2010 1742 1752
48. R. Krishna, and L.D. Mayer Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs Eur J Pharmaceut Sci 11 2000 265 283
49. M. Yu, A. Ocana, and I.F. Tannock Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit Cancer Metastas Rev 32 2013 211 227
50. Z. Binkhathlan, and A. Lavasanifar P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives Current Cancer Drug Targets 13 2013 326 346